Softwr

Research · head to head

Form Bio vs Schrodinger

Form Bio logo

Form Bio

Research

Computational platform for cell and gene therapy design and manufacturability

From
On request
Rated
-
Full reviewWebsite
Schrodinger logo

Schrodinger

Research

Physics based molecular modelling and drug discovery software, licensed by token pool

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Form Bio the company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.; Schrodinger licences are sold as token pools rather than unlimited module access, so a department can be blocked mid campaign because colleagues are consuming concurrency, and expanding the pool is a new commercial negotiation rather than a setting.
  • They diverge on capability: Form Bio covers FormManufacturing, Schrodinger covers Maestro.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Form Bio and Schrodinger actually diverge.

Attributes where Form Bio and Schrodinger differ
AttributeForm BioSchrodinger
PlatformsWeb, CloudLinux, macOS, Windows, Web

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Form Bio

  • FormManufacturing
  • Payload design optimisation
  • Genome integrity analysis
  • Manufacturability prediction
  • In silico workflows
  • Scale-up monitoring
  • Cell and gene therapy focus
  • Collaboration

Only in Schrodinger

  • Maestro
  • Glide
  • FEP+
  • Desmond
  • Jaguar
  • LiveDesign
  • Materials Science suite

What people use each for

The jobs each tool is most often brought in to do.

Form Bio

  • A gene therapy developer discovering manufacturability problems with an AAV construct late in process development and wanting to move that analysis earliernot Schrodinger
  • A biotech comparing several candidate payload designs in silico before committing to expensive production runsnot Schrodinger
  • A CDMO characterising what a client construct actually produces against what was specifiednot Schrodinger
  • A programme team needing genome integrity evidence to support regulatory conversations about product consistencynot Schrodinger

Schrodinger

  • A medicinal chemistry programme using FEP+ to prioritise which analogues to synthesise, where avoiding a handful of wasted syntheses pays for the licencenot Form Bio
  • A structure based design campaign that needs docking at scale against a target with a good crystal structurenot Form Bio
  • A materials group modelling polymer or electrolyte properties before committing to formulation experimentsnot Form Bio
  • A university modelling group that qualifies for the published academic site licence and needs Maestro across a teaching and research cohortnot Form Bio

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Form Bio

  • The company has pivoted twice since spinning out of Colossal Biosciences in 2022, from general computational life sciences to cell and gene therapy and then to AAV manufacturability, so any evaluation more than a year old describes a product that is no longer the commercial focus.
  • The current offering launched AAV-focused, so developers working in lentiviral, mRNA or cell therapy modalities are outside the scope the platform was built and validated for.
  • No pricing is published and engagements are scoped per programme, which makes it impossible to size the commitment before entering a sales process.
  • This is a young venture-funded company whose analyses feed regulatory-facing decisions, so continuity of the vendor over a multi-year development programme is a genuine diligence question rather than a formality.
  • Predictive manufacturability models need real production data to be trustworthy, and the value depends on how much of that a young vendor has accumulated, which is difficult for a buyer to verify independently.

Schrodinger

  • Licences are sold as token pools rather than unlimited module access, so a department can be blocked mid campaign because colleagues are consuming concurrency, and expanding the pool is a new commercial negotiation rather than a setting.
  • Commercial pricing is not published and is negotiated against modules, cores and term, so two companies of similar size can pay very different amounts and neither can benchmark the other.
  • FEP+ needs substantial GPU capacity that is not included in the licence, so the real annual cost includes cloud or on premise hardware that often rivals the software line item.
  • The tools require trained computational chemists to produce trustworthy results, and an organisation without that function will generate predictions it cannot interpret or defend to its own medicinal chemists.
  • Schrodinger runs its own internal drug discovery pipeline alongside selling software to discovery companies, and some prospective customers treat that dual role as a conflict when discussing proprietary targets, which slows procurement even where contractual separation exists.

Pricing, plan by plan

Form Bio

On request
  • FormManufacturing$undefined/year
    • Pricing only through a sales process
    • Scoped per therapeutic programme rather than per seat
    • AAV-focused offering at launch

Schrodinger

On request
  • Commercial licence$undefined/year
    • Quoted per customer against modules, cores and licence term
    • Applications draw from a shared token pool that caps concurrency
    • GPU compute for FEP+ and Desmond is a separate cost, on premise or cloud
  • Academic site licence$undefined/year
    • Published academic entry around 7,500 USD a year for a premium package with a token allocation
    • Restricted to academic and research use, not work supporting a commercial enterprise
    • Maestro generally unrestricted with tokens shared for compute heavy applications

Which should you pick?

Choose Form Bio if

  • You need formmanufacturing.
  • You work on Web, Cloud.
  • You also want payload design optimisation.
Form Bio review

Choose Schrodinger if

  • You need maestro.
  • You work on Linux, macOS, Windows, Web.
  • You also want glide.
Schrodinger review

Questions people ask

Is Form Bio or Schrodinger better?
Neither clearly leads. Form Bio starts at On request and Schrodinger at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Form Bio or Schrodinger?
Form Bio starts at On request and Schrodinger at On request.
Does Form Bio or Schrodinger run on more platforms?
Form Bio runs on Web, Cloud. Schrodinger runs on Linux, macOS, Windows, Web.
What is Form Bio best used for?
Form Bio is most often used for a gene therapy developer discovering manufacturability problems with an aav construct late in process development and wanting to move that analysis earlier, a biotech comparing several candidate payload designs in silico before committing to expensive production runs, a cdmo characterising what a client construct actually produces against what was specified, a programme team needing genome integrity evidence to support regulatory conversations about product consistency. Of those, a gene therapy developer discovering manufacturability problems with an aav construct late in process development and wanting to move that analysis earlier and a biotech comparing several candidate payload designs in silico before committing to expensive production runs are not what Schrodinger is typically brought in for.
What can Form Bio do that Schrodinger cannot?
Form Bio covers FormManufacturing, Payload design optimisation, Genome integrity analysis, Manufacturability prediction. Schrodinger covers Maestro, Glide, FEP+, Desmond.

Answered from the vendors’ own pages

Form Bio: What does Form Bio sell now?

FormManufacturing, launched in 2026, an AAV-focused platform for predicting, optimising and monitoring manufacturability of genetic medicines from construct design through scale-up.

Schrodinger: How is Schrodinger software licensed?

Annual licences with a shared token pool. Tokens cap how much you can run at once rather than which modules you own outright.

Form Bio: Is it still a general bioinformatics platform?

No. It has narrowed from broad computational life sciences tooling to cell and gene therapy, and within that to AAV.

Schrodinger: Is there published pricing?

Only for academic site licences, which start around 7,500 USD a year for a premium package. Commercial pricing is quoted.

Form Bio: Where did the company come from?

It spun out of Colossal Biosciences in 2022.

Schrodinger: Do I need my own GPUs?

For FEP+ and Desmond in practice yes, or cloud GPU capacity. Compute is not included in the licence.

Form Bio: Is pricing published?

No. Engagements are scoped per programme through a sales process.

Schrodinger: Does Schrodinger compete with its customers?

It runs its own drug pipeline as well as selling software. It manages this through contractual separation, but buyers with sensitive targets should raise it during procurement.

Share

Related pages

More on Form Bio

More on Schrodinger

Keep looking

Other head to heads